Savara Inc. Reports Q3 2025 Financial Results

Savara ( (SVRA) ) has released its Q3 earnings. Here is a breakdown of the information Savara presented to its investors.

Savara Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare respiratory diseases, with its primary program being the investigational inhaled biologic MOLBREEVI for autoimmune pulmonary alveolar proteinosis. In its latest earnings report for the quarter ended September 30, 2025, Savara reported a net loss of $29.6 million, reflecting increased operating expenses primarily due to research and development activities. The company’s cash and cash equivalents stood at $16.3 million, with short-term investments of $108.1 million, indicating a robust liquidity position to support ongoing operations. Key financial highlights include a significant increase in research and development expenses to $20.6 million for the quarter, alongside a rise in general and administrative expenses to $9.6 million. Despite the losses, the company successfully raised approximately $140 million through a public offering, bolstering its financial resources. Looking ahead, Savara remains focused on advancing MOLBREEVI through clinical trials, with management expressing confidence in their ability to fund operations for at least the next twelve months. The company plans to continue leveraging its cash reserves and strategic financing options to support its development efforts and achieve regulatory milestones.